Johnson & Johnson (JNJ)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $687.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Johnson & Johnson (JNJ) Stock Forecast
Analysts expect Johnson & Johnson (JNJ) to earn $11.12 per share in the fiscal year ending Dec 31, 2026, on revenue of $101.22B. Of 23 analysts, 16 rate the stock Buy or Strong Buy, 6 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 70% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 21.7% |
| Buy | 11 | 47.8% |
| Hold | 6 | 26.1% |
| Sell | 1 | 4.3% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 23
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 4.5% and revenue estimates rise 6.5%.
- Fiscal year ending Dec 31, 2026
- $11.12
- EPS consensus, revenue $101.22B
- Fiscal year ending Dec 31, 2027
- $11.62
- EPS consensus, revenue $107.75B
- Next report
- Jan 26, 2027
- Confirmed, after the close
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $11.12 | $11.05 to $11.28 | 21 | $101.22B | $101.00B to $101.47B | 21 |
| Dec 31, 2027 | $11.62 | $10.75 to $13.34 | 22 | $107.75B | $106.30B to $109.95B | 21 |
Quarterly Estimates
The EPS consensus falls from $2.94 for the quarter ending Dec 31, 2026 to $2.67 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.94 | $2.80 to $3.10 | 18 | $26.69B | $25.70B to $28.02B | 17 |
| Mar 31, 2027 | $2.67 | $2.57 to $2.87 | 7 | $25.55B | $25.30B to $26.20B | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 6 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.6% from $11.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $11.12 | $11.12 | $11.06 | $11.08 | $11.05 | +0.6% |
| Fiscal year ending Dec 31, 2027 | $11.62 | $11.62 | $12.32 | $12.45 | $12.31 | -5.6% |
| Quarter ending Mar 31, 2027 | $2.67 | $2.68 | $2.80 | $2.78 | $2.78 | -3.6% |
Frequently Asked Questions About JNJ
What is the JNJ stock forecast?
Consensus analyst estimates put Johnson & Johnson's EPS at $11.12 for the fiscal year ending Dec 31, 2026, on revenue of $101.22B. The consensus rating from 23 analysts is Buy.
How do analysts rate JNJ stock?
Of 23 analysts covering Johnson & Johnson, 5 rate it Strong Buy, 11 Buy, 6 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from JNJ next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $11.12, with estimates from $11.05 to $11.28 from 21 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $11.62, with estimates from $10.75 to $13.34 from 22 analysts.
What revenue do analysts expect from Johnson & Johnson next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $101.22B, with estimates from $101.00B to $101.47B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $107.75B, with estimates from $106.30B to $109.95B.
How many analysts cover JNJ?
23 analysts rate Johnson & Johnson stock, and 21 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
JNJ pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts